Taken together, our results demonstrate that by combining EGFR and KRAS mutation analysis in NSCLC patients with non-squamous cell histology, decisions on appropriateness of EGFR TKI therapy can be made in 27% of our patient cohort. Here, EGFR is linked to non-small cell lung carcinoma.